GNTA
Genenta Science SpA (GNTA)
Healthcare • NASDAQ • $0.63-0.65%
- Symbol
- GNTA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.63
- Daily Change
- -0.65%
- Market Cap
- $14.77M
- Trailing P/E
- N/A
- Forward P/E
- -0.96
- 52W High
- $10.00
- 52W Low
- $0.59
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.73
Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Company websiteResearch GNTA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.